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Abstract
Background: Curcuma has long been used as an anti-inflammatory agent in inflammatory bowel disease. Since
gastrointestinal motility is impaired in inflammatory states, the aim of this work was to evaluate if Curcuma Longa had any
Methods: The biological activity of Curcuma extract was evaluated against Carbachol induced contraction in isolated mice
intestine. Acute and chronic colitis were induced in Balb/c mice by Dextran Sulphate Sodium administration (5% and 2.5%
respectively) and either Curcuma extract (200 mg/kg/day) or placebo was thereafter administered for 7 and 21 days
respectively. Spontaneous contractions and the response to Carbachol and Atropine of ileum and colon were studied after
colitis induction and Curcuma administration.
Results: Curcuma extract reduced the spontaneous contractions in the ileum and colon; the maximal response to Carbachol
was inhibited in a non-competitive and reversible manner. Similar results were obtained in ileum and colon from Curcuma
fed mice. DSS administration decreased the motility, mainly in the colon and Curcuma almost restored both the
spontaneous contractions and the response to Carbachol after 14 days assumption, compared to standard diet, but a
prolonged assumption of Curcuma decreased the spontaneous and Carbachol-induced contractions.
Conclusions: Curcuma extract has a direct and indirect myorelaxant effect on mouse ileum and colon, independent of the
anti-inflammatory effect. The indirect effect is reversible and non-competitive with the cholinergic agent. These results
suggest the use of curcuma extract as a spasmolytic agent.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic
inflammatory conditions of the intestinal tract: they are the
consequence of environmental influences, genetic disorders,
intestinal microbiota alterations, leading to an abnormal immune
response with inflammation [1,2]. A combination of all these
factors is probably necessary for clinical expression of the disease
[3]. Although the inflammation may remain limited to certain
gastrointestinal segments, the function of the whole tract is altered
[4,5,6]. Intestinal motility has been reported to be impaired in
patients with Inflammatory Bowel Disease (IBD) [7,8]. Inflamma-
tion is associated with decreased colonic mixing and haustra
formation, but increased propulsive motility, leading to diarrhea
[9]. The physiopathology of dysmotility in IBD has not been
completely elucidated: a selective hyperactivity 10] of the non-
adrenergic, non-cholinergic inhibition has been documented in
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human colon. Disruption in intracellular Ca2+ mobilization and
signaling [11], defective norepinephrine release [12], impairment
of the protease-activated receptor 2 [13], defective inhibitory
neuron dependent relaxation in the colon [14] have been reported
in the experimental animal. Conventional therapy for IBD is
hampered by toxicity, intolerance or slow onset of action [15].
Recently, anti-tumour necrosis factor alpha and other biologic
agents have been introduced [3,16–18], but their safety in long
term treatment has not been proved jet. Therefore, the use of
natural substances with no side effects, though not so powerful
effective as drugs so far employed, is encouraged, at least in the
prevention and in the maintenance of remissions of IBD.
Unfractionated or low-molecular-weight heparin, omega-3 poly-
unsaturated fatty acids, microbes and microbial products are
currently under investigation [3].
Curcuma longa (turmeric) is a perennial herb, cultivated in the
Southeast Asia [19]. In traditional medicine it has been used for
centuries due to its antitumor, antimicrobial, anti-inflammatory,
antioxidant properties and it presents acethylcholinesterase
inhibitory activity [20–25].
Turmeric chemicals include curcumin (the primary constituent
responsible for its yellow color), demethoxycurcumin, and
bisdemethoxycurcumin, as well as volatile oils, sugars, proteins,
and resins, curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-
heptadiene-3,5-dione) being the most studied compound [26]. The
anti-inflammatory activity of curcumin has been investigated in
various in vitro and in vivo studies [27–30]. In the experimental
animal a turmeric extract has been shown to prevent the
development of Trinitrobenzene Sulfonic Acid (TNBS)-induced
colitis [28,31–33] through the inhibition of signal transduction
pathways critical to inflammatory responses, such as AP-1, protein
kinase C, and NF-kB [34,35–37]. Moreover, it has been shown to
prevent inflammation through blockage of NF-kB in the mucosa
in Dextran Sodium Sulphate (DSS) induced chronic colitis [38]
and to inhibit immunostimulatory functions of dendritic cells by
blocking MAPKs and NF-kB activation [39]. In addition,
Curcuma, in a randomized, double-blind, placebo-controlled trial,
has been shown to be effective and safe in maintaining ulcerative
colitis remission, and to decrease active oxygen species production
[30]. So far, many data are available about Curcuma longa anti-
inflammatory properties, but little and conflicting information is
available about the effect of Curcuma longa on intestinal motility
[40–42]. The wide clinical use of Curcuma longa as an anti-
inflammatory agent in IBD and its empiric use in diarrhea in
eastern countries prompted the present investigation in order to
evaluate whether Curcuma exerts some myorelaxant effect on
intestinal ileal and colonic motility in healthy intestinal segments,
whether this effect, if any, is also observed in DSS induced acute
and chronic experimental colitis, and, finally, whether this effect is
independent of the anti-inflammatory effect.
Methods
Animals
One hundred thirty male Balb/c mice (8 weeks old, 25–30 g
b.w.) (Charles Rivers Laboratories, Calco, LC, Italy) were
enrolled: a higher number of animals than required were recruited
in order to compensate for the drops out in the course of the
experiments, due to the severity of colitis compelling to stop the
experiments, according to the Recommendations of the Ethical
Committee of the University of Bologna for Animal Experiments.
The animals were kept at constant light/dark cycling and constant
room temperature of 22uC. They were fed the usual commercial
diet and were allowed water ad libitum.
Mice were divided into 5 groups: a first group of healthy
animals (n 15) was used as donors of intestinal segments in order to
evaluate the in vitro effect of Curcuma extracton intestinal motility
parameters by antagonism of Carbachol-induced contraction in
isolated ileum and distal colon. In a second and a third group of
animals Dextran Sodium Sulphate (DSS) (MP Biomedicals, Solon;
OH, USA; m.w. 36.000–50.000) chronic (n 50) and acute(n 25)
colitis (see below) respectively were induced and the effect of DSS
on the Disease Activity parameters and intestinal motility were
evaluated. After colitis induction, Curcuma extract was orally
administered (200 mg/kg b.w./day) and, at fixed time intervals,
(see below), the Disease Activity parameters and intestinal motility
were evaluated. A fourth group of animals (n 14) was used as
controls and a fifth group of mice (n 6) were used as Curcuma fed
control, after oral administration of Curcuma over seven days. For
all groups of animals, intestinal histology, spontaneously and
Carbachol-induced motility were assessed. The effect of Atropine
in Carbachol-induced contraction was also studied in order to get
more insights into the mechanism of action of Curcuma extract on
the ileal and colonic contraction.
Study protocol. In vitro studies. The in vitro effect of curcuma
was evaluated on isolated mice ileum and distal colon segments.
In vivo studies. Chronic colitis: chronic colitis was induced
in mice by oral administration of DSS (2.5%, w/v) in drinking
water (see Text S1). Throughout the period, the animals were fed
the usual commercial diet. After 52 days colitis induction, mice
were divided into two groups: one group was switched to a
Curcuma (200 mg/Kg b.w.) (Indena, Milan, Italy) added diet, the
other continued the usual diet. Throughout the experiment, the
Disease Activity Index (DAI) was evaluated. After colitis induction
and after 7, 14, 21 days of either Curcuma extract added diet
(200 mg/kg/b.w.) or standard diet administration, 6 mice of each
group were sacrificed and the following parameters were
evaluated: colon length, intestinal histology and motility. Acute
colitis: acute colitis was induced in mice, by addition of DSS (5%
w/v) in the drinking water for 7 days. After this period, the mice
were randomly allotted to two groups, one group continued the
standard usual diet, the other was switched to a diet similar to the
previous but added with Curcuma (200 mg/kg b.w.); after 7 days,
the animals were sacrificed. The same parameters as in the
previous group were recorded. Control animals. 14 mice were
studied as controls and the same parameters as above reported
were evaluated.
Curcuma fed controls. 6 mice were fed Curcuma added
diet over 7 days and thereafter sacrified and similarly studied. A
schematic representation of the study is reported in Figure 1.
DSS Colitis Induction
Acute and chronic colitis were induced by DSS administration
according to Wirtz [43] (see Text S1). The chronic colitis model
has been shown to induce a long lasting colonic inflammation in
mice [43].
Assessment of Colitis
Evaluation of disease activity index (DAI )and colon
length. Disease Activity Index (DAI) was calculated for each
animal as described by Fitzpatrick et al. [44]. The colon was
individuated as the segment between the ileo-cecal valve and the
rectum and the length was measured (see Text S1 and Table S1).
Curcuma Extract Administration
Mice were on a 4RF21diet (Mucedola S.r.l., Milan, Italy).The
4RF21 complete food was added with Curcuma (Indena Spa,
Milan, Italy) extract at a final concentration of 1 g/kg. The
Intestinal Myorelaxant Effect of Curcuma
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delivery form of Curcuma used in the present study is a patented
formulation of Curcumin (Free Curcumin; Curcuminglucuronide;
Curcuminsulphate), a dietary phenolic, with soylecithin. The two
compounds form a non-covalent adduct in a 1:2 weight ratio, and
two parts of microcrystalline cellulose are then added to improve
formulation (www.phytosomes.info).
The chemical preparation was proved to be 18–22% pure by
HPLC total curcuminoids content. Each mouse received 200 mg/
Figure 1. Photomicrographs of hematoxylin and eosin staining of Colon sections from DSS (5%w/v over 7 days) treated mice,
before(a) and after 7 days Curcuma extract administration (b) and from DSS (2.5%,w/v, three cycles over 52 days) (c) and after 21
days Curcuma extract administration (d). (a) Intestinal mucosal with edema and marked/moderate acute inflammation composed by
neutrophils, lymphocites and plasmacells. The intestinal glands show moderate regenerative hyperplasia.(H&E 106). (b) Moderate mucosal
inflammation composed by lymphocytes and some neutrophils; the intestinal glands show mild regenerative hyperplasia. (H&E 56). (c) Chronic
colitis. The mucosa shows a chronic infiltrate composed by lymphocytes and plasmacells. The glands show mild regenerative hyperplasia. (H&E 56).
(d) Intestinal mucosal with mild inflammation composed by lymphocytes, plasmacells and rare neutrophils. The submucosa shows many foam
macrophages (H&E 206).
doi:10.1371/journal.pone.0044650.g001
Table 1. Histological score.
Grade Morphological features
0 No inflammatory infiltration of neutrophyls and eosinophils in the lamina propria.
1 Mild and focal infiltrate of neutrophils and eosinophils in the lamina propria with mild crypt aggression.
2 Moderate infiltrate of neutrophils and eosinophils in the lamina propria with moderate crypt aggression.
3 Marked and diffuse infiltrate of neutrophils and eosinophils in the lamina propria with marked crypt aggression.
doi:10.1371/journal.pone.0044650.t001
Intestinal Myorelaxant Effect of Curcuma
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kg per day, i.e. the human equivalent dose for mice [45] (see Text
S1).
Ethics statement. The work has been conducted according
to relevant National and International Guidelines. All experiments
were conducted in conformity with the Public Health Service
Policy on Humane Care and use of Laboratory Animals and
approved by the Ethical Committee of the University of
Bologna(PR 22.03.10). The animals were kept at constant
temperature, light/dark cycle. Whenever a mouse gave signs of
discomfort, the experiment was interrupted and the animal was
switched to plain water and the usual commercial diet and
excluded from the study.
Experimental Procedure
Twenty four hours before the experiments, food was withdrawn
and water was maintained ad libitum. The animals were sacrificed
by cervical dislocation. The abdomen was opened by median
laparotomy and exposed. A portion of jejunum, immediately after
the Treitz was removed (1.5 cm) and retained for histological
examination. A 1.5 cm length segment of the terminal ileum,
immediately proximal to the ileo-cecal valve and a 2.5 cm region
of the distal colon were identified, slightly cleaned with Krebs
solution to remove fecal residues and dissected into two parts: one
part was placed in 10% formalin for subsequent histological
analysis, a second was retained for immediate in vitro motility
Table 2. Histological score of inflammatory damage of the colon in mice after acute and chronic DSS induced colitis and after
curcuma extract (200 mg/kg/day) or standard diet administration: range of 6 animals.
Histological Grading
After colitis induction After 7 days After 14 days After 21 days
Controls 0 0 0 0
Acute
colitis
followed by standard
diet
3–3 2–3
followed by curcuma
extract
3–3 1–2
Chronic colitis followed by standard
diet
3–3 2–3 2–3 2–2
followed by curcuma
extract
2–3 2–2 1–2 0–1
The histological score was performed by blind pathology to the study design.
doi:10.1371/journal.pone.0044650.t002
Figure 2. A schematic representation of the experimental design.
doi:10.1371/journal.pone.0044650.g002
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studies (see below). Stools were analyzed for consistency and blood
traces.
Histology
The sections of ileum and colon specimens were preserved in
10% neutral buffered formalin for about 48 hours and routinely
processed. Five micron sections were cut and stained with
Haematoxylin and Eosin (H&E).The histological preparations
were examined histologically on a blinded basis.
Histological grading. Acute colitis is characterised by
intense inflammatory cell infiltrate, crypt abscesses, mucin
depletion, and surface ulceration, that are the main histological
features of acute activity. The hallmark is the presence of
neutrophils and eosinophils infiltrating lamina propria and crypt
epithelium.
Chronic colitis is characterized chronic inflammatory cells,
plasma cells and lymphocytes in the lamina propria, distortion of
the normal architecture of colonic mucosa, including crypts
branching and regeneration. These morphological features induce
a variety of altered shapes and sizes of crypts and changes in
surface contours. Basal accumulation of lymphocytes and plasma
cells with hyperplasia of lymphoid tissue probably represents an
early immunologic manifestation of the underlying disease.
Therefore, according to the amount of acute and chronic
inflammatory cell infiltrate in colon and in small bowel slides colitis
was classified in four grades as reported in Table 1.
Functional Studies
The animals were sacrificed by cervical dislocation, and the
organ (ileum and distal colon) required was set up rapidly under a
suitable resting tension in 15 mL organ bath containing appro-
priate physiological salt solution (PSS) consistent warmed (see
below) and buffered to pH 7.4 by saturation with 95% O2–5%
CO2 gas.
Mouse ileum. The terminal portion of ileum (immediately
proximal to the ileo-caecal junction) was cleaned, and segments
1 cm long of ileum were set up under 1 g tension at 37uC in
organ baths containing Tyrode solution of the following
composition (mM): NaCl, 145; KCl, 2.6; CaCl2?2H2O, 1.5;
MgCl2?6H2O, 0.73; NaH2PO4?2H2O, 0.33; NaHCO3, 4.8;
glucose, 11.1 [46]. Each segments was set up under 1 g tension
in the longitudinal direction along the intestinal wall. Tissue
were allowed to equilibrate for at list 30 min during which time
the bathing solution was changed every 10 min. Concentration-
response curves were constructed by cumulative addition of the
agonist Carbachol (CCh). The concentration of agonist in the
organ bath was added only after the response to the previous
addition had attained a maximal level and remained steady.
Contractions were recorded by means of displacement trans-
ducer (FT. 03, Grass Instruments, Quincy, MA) using Power
Lab software (ADInstruments Pty Ltd, Castle Hill, Australia). In
all cases, parallel experiments in which tissues did not receive
any antagonist were run in order to check any variation in
Figure 3. Inhibition of spontaneous motility of ileum (upper panel) and colon (lower panel) by curcuma extract. The segments were
suspended in organ baths containing gassed warm Krebs solution under a load of 1 g maintained at 37uC. Tension changes in longitudinal muscle
length were recorded. In control conditions (a), after curcuma extract additioned medium (b) and after washing (c).For details see Methods section.
doi:10.1371/journal.pone.0044650.g003
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sensitivity. Concentration–response curves to agonist were
obtained at 30 min intervals, the first one being discarded
and the second one used as control. A new concentration-
response curve to agonist was obtained following incubation
with the antagonist (Atropine or Curcuma extract). Tension
changes were recorded isotonically.
Mouse distal colon. A segment of about 2 cm of the distal
colon was transected, rinsed with Krebs solution of the following
composition (mM): NaCl, 119; KCl, 4.5; CaCl2, 2.5;
MgSO4?7H2O, 2.5; KH2PO4?2H2O, 1.2; NaHCO3, 25; glucose,
11.1; the mesenteric tissue was removed. The segments were
suspended in organ baths containing gassed warm Krebs solution
under a load of 1 g maintained at 37uC. Tension changes in
longitudinal muscle length were recorded. Tissues were allowed to
equilibrate for at least 30 min during which time the bathing
solution was changed every 10 min. Concentration–response
curves to agonist Carbachol (CCh) were recorded isotonically
and obtained at 30 min intervals, the first one being discarded and
the second one taken as control. Following incubation with the
antagonists (Atropine or Curcuma extract), a new concentration–
response curve to agonist was obtained. Longitudinal muscle
contractions were recorded isotonically by the mean of force
displacement transducer (FT 03, Grass Instruments, Quincy, MA)
using Power Lab software (ADInstruments Pty Ltd, Castle Hill,
Australia). In all cases, parallel experiments in which tissues did
not receive any antagonist were run in order to check any
variation in sensitivity.
Statistical Analysis
Determination of Dissociation Constants. Functional
activity of CCh and antagonism of Atropine and Curcuma
extract vs CCh induced contraction, was determined in gut
segments. The biological results of agonist CCh was expressed
as pEC50 values. pEC50 values represent the –logEC50. EC50
values are the means 6 SE of at least four independent
experiments and were calculated by a non-linear regression
curve-fitting computer program [47].
In functional experiments, dose ratios at the EC50 values of the
agonist were calculated at three to five antagonist concentrations,
and each concentration was tested from two to four times. The
results are expressed as pA2 values [48,49]. Data are presented as
means 6 SE of n experiments. Differences between mean values
were tested for significance by Student’s t-test. P value less than
0.05 was considered significant.
The antagonism activity to CCh of curcuma extract was
estimated by determining the concentration of the non-
competitive antagonist that inhibited 50% of the maximum
response to the agonist. Three different antagonist concentra-
tions were used and each concentration was tested at least three
times. A pharmacological computer program was used to
analyze data [49]. It was always verified that EC50 values for
the agonist in tissues receiving only the solvent were not
significantly different (P.0.05) from control values. In other
cases experiments were discarded. Figures were created using
GraphPad software [50].
Materials
Carbachol, Atropine and all chemicals were obtained from
Sigma (St. Louis, MO, USA). Curcuma was gently supplied by
Indena (Indena Spa, Milan, Italy).
Figure 4. Effect of curcuma extract on carbachol-induced contraction in isolated mouse ileum (A) and distal colon (B). a) Cumulative
concentration-response curves were obtained before and after exposure to curcuma extract for 30 min. Each point is the mean 6 SEM (n =3–5). b)
Time course of curcuma extract effect on Carbachol-induced contraction in isolated mouse ileum (A) or distal colon (B) (100%). Cumulative
concentration-response curves were obtained before and after exposure to curcuma extract (0.05 mg/mL) for 5, 30 and 45 min. Each point is the
mean 6 SEM (n =3–5). c) Time course of curcuma extract (0.05 mg/mL) on carbachol-induced contraction in isolated mouse ileum (A) and distal
colon (B). Cumulative concentration-response curves were obtained before and after exposure to curcuma extract (0.05 mg/mL) and following 5, 30
and 60 min washing. Data are the mean 6 SEM (n = 3–5). Where error bars are not shown, these are covered with the point itself.
doi:10.1371/journal.pone.0044650.g004
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Results
Induction of Acute and Chronic colitis Assessment of
Acute and Chronic Colitis and Evaluation of the Response
to Curcuma Extract (see Text S1)
Histological parameters. the histological score is reported
in Table 2. Both the ileum and the distal colon of the control mice
demonstrated a very mild lymphocytic infiltration, typical for the
‘‘physiological inflammation’’ observed in murine intestine under
normal conditions [51].
Acute DSS-induced colitis is characterized by histological
findings such as severe edema, infiltration of inflammatory cells
with granulocytes into both the mucosa and the submucosa, with
destruction of the epithelial cells: seven days after withdrawal of
DSS, the histological analysis indicated that the severity of colitis
was higher in DSS-treated mice assuming standard diet compared
to Curcuma treated mice. In chronic DSS induced colitis, chronic
inflammatory cells sometimes with mild neutrophil infiltrate were
present in the mucosa and submucos; in some cases we observed a
mild epithelial aggression. Twenty days after suspension of DSS,
Curcuma extract administration improved the histological findings
compared to the standard diet control group (Figure 2). Not any
pathological alterations were found in the duodenum and
jejunum.
Colon length and Disease Activity Index (DAI). the results
are reported respectively in Figure S1, S2 and S3.
Functional Studies
Spontaneous motility in ileum and colon. In control mice,
spontaneous contractions in the ileum and colon were constant in
amplitude and frequency. The ileal and colonic contractions in
basal conditions were considered as 100% and the contractions
in pathological conditions were compared with the control
motility. In vitro curcuma extract inhibited the spontaneous
Figure 5. Potency of CCh (pEC50) (dark blu) and atropine (pA2) (light blu) on ileum (a) and on distal colon (red) and (pink)
respectively. (1): control mice. (2): mice with acute DSS induced colitis; (3): acute colitis mice fed the usual diet over 7 days after stopping DSS; (4):
acute colitis mice fed curcuma over 7 days after stopping DSS. The dashed line shows the control values for CCh pEC50. The dotted line shows the
control values for Atropine pA2. When error bar are not shown these are covered by the point itself. The contraction induced by Carbachol and the
antagonistic effects of Atropine were used as reference. In healthy animals Carbachol is by 3.55 times more potent on the ileum than on the colon.
Atropine presents similar antagonistic activity on both tissues: these data have been used as a comparison with the effect of Carbachol and Atropine
on tissues from acute colitis animals. Carbachol pEC50 decreased by 3.80 times in the ileum and 1.58 times in the colon and Atropine pA2 was reduced
by 1.86 and 1.12 times respectively in the ileum and the colon, compared with the corresponding intestinal segments of control mice. Curcuma
administration improved the response to Carbachol in the colon, but not in the ileum, also if it did not completely restore the normal values.
doi:10.1371/journal.pone.0044650.g005
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intestinal contraction by 100% both in ileum and colon
(Figure 3). In vivo, when orally administered over one week to
healthy mice, the spontaneous motility in the ileum and colon
was reduced by 30%; the contractions were constant in
frequency and amplitude. In acute colitis, intestinal motility
was increased by 230% in the ileum; the contractions were
highly irregular in amplitude and frequency; they were reduced
by 100% in the colon; Curcuma extract administration over one
week to mice reduced the by 50% the spontaneous contraction in
ileum without any significant effect on the colon, while standard
diet administration did not modify significantly ileal and colonic
contractions. In chronic DSS colitis, spontaneous contractions
increased by 400%and 300% respectively in the ileum and colon.
They were of irregular amplitude and frequency. Seven days
after curcuma administration, a partial normalization was
observed in both the ileum and the colon; 14 days after
Curcuma administration the basal ileal and colonic motility were
normalized and were of constant amplitude and frequency. A
longer administration (21 days) inhibited the basal spontaneous
activity of the ileum and colon. Standard diet administration did
not substantially modify the intestinal basal motility since only a
partial recovery was observed with time.
Response to Carbachol and Atropine. Curcuma extract effect
on isolated ileum and colon. Initially we have evaluated the
antispasmodic activity of Curcuma longa Linn Extract from rhizomes
on ileum and distal colon. Experiments performed in mice ileum
and colon showed that Curcuma extract inhibited the maximum
response to Carbachol in a non-competitive manner. These results
show that the extract produce a smooth muscle relaxation effect on
mice ileum and colon, as previously described for Guinea Pig [42].
Furthermore, this blockade was reversed after 30 min tissue
washing (Figure 3). The IC50 value for Curcuma extract was
0.03 mg/ml in ileum and 0.04 mg/min distal colon respectively
(Table S2). In both cases, the agonist activity was comparable.
Effect of Carbachol and Atropine on ileum and colon from control mice. In
order to evaluate the effects of Curcuma extract on the intestinal
muscular layers of ileum and colon, we have used as reference the
contraction induced by Carbachol and the antagonistic effects of
Atropine. Figure 4 reports Carbachol pEC50 and Atropine pA2 on
ileum and colon respectively.
As it can be observed (for data see Table S3), Carbachol is by
3.55 times more potent on the ileum than on the colon. Atropine
presents similar antagonistic activity on both tissues: these data
have been used as a comparison with the effect of Carbachol and
Atropine on tissues from DSS treated animals (acute and chronic
colitis ) and after Curcuma extract or placebo administration.
Functional Study in DSS Mice Smooth Muscle
Acute colitis. Acute colitis was induced with DSS (5%, w/v)
over 7 days in the drinking water, after which one group went on
assuming the usual commercial diet, the other was switched to
curcuma (200 mg/kg/day) added diet for 7 days.
Carbachol induced contraction was reduced: in fact Charbacol
pEC50 decreased by 3.80 times in the ileum and 1.58 times in the
colon compared to the respective control intestinal segments
(Figure 5; for data see Table S4). Similarly, the effect of Atropine
was decreased: pA2 was reduced by 1.86 and 1.12 times
respectively in the ileum and the colon, compared with the
corresponding intestinal segments of control mice. Both the effects
were stronger in the ileum than in the colon: This finding is at
variance with the histological damage, which is limited to the
colon, resembling the histopathological features of UC. Seven days
Curcuma extract administration improved the response to
Carbachol in the colon, but not in the ileum, both in comparison
with the response of colon from mice with acute disease and mice
assuming control diet, also if it did not completely restore the
normal values. The response to Atropine was decreased both in
the Curcuma added diet group and in the controls. In the ileum,
Curcuma extract administration did not even partially restore the
response to Carbachol and Atropine.
In order to evaluate whether Curcuma extract had any effect on
normal intestine and compare it, if any, with the effect of Curcuma
on the intestine from mice with DSS induced acute colitis, we have
administered Curcuma extract over 7 days to control mice. As
shown in Table 3, Curcuma extract, when added to diet decreased
the response to Carbachol in the ileum, by 1.69 and in the colon,
by 1.20, while it increased in both the response to Atropine. As it
can be observed, the effect was greater in the ileum.
Chronic colitis. Chronic colitis was induced in mice with
DSS (2.5%w/v), three ‘‘8 days’’ cycles, with plain water between,
for a total of 52 days, after which one group continued the control
diet for 7 days, the other was switched to curcuma (200 mg/kg/
day) over 7 days. After colitis induction, animals were either
switched to curcuma extract administration or continued the usual
diet. They were then sacrificed after 7, 14, 21 days and the two
groups of animals were compared (Figure 6; for data see Table S5).
Discussion
Scanty data are available in literature about the effect of
Curcuma on intestinal motility. In healthy humans, an indirect
evidence that Curcuma activates bowel motility has been
produced by hydrogen breath [40]. On the contrary, Curcuma
increases intestinal transit time in albino rats and ileal motility in
Guinea Pig, consistently with the traditional use of curcumin in
disorders of altered intestinal motility [41–42]. The use of turmeric
as an anti-inflammatory agent in IBD and the traditional empiric
use of Curcuma as an antidiarrheal symptomatic drug in
functional disorders of the gastrointestinal tract suggested an
effect on intestinal motility.
The GI tract function is under neural control, extrinsic
autonomic nerves influencing the activity of enteric neurons
Table 3. Agonist (carbachol) and antagonist (atropine)
affinities expressed as pEC50 or pA2 respectively on the
isolated mice ileum and distal colon of control mice and mice
fed Curcuma extract over seven days.
Standard Dieta CurcumaExtb
ileum CCh pEC50
c 6.6360.04 6.4060.03
Atropine pA2
d 8.8960.03 9.1660.02
colon CCh pEC50
c 6.0860.01 6.0060.01
Atropine pA2
d 8.8960.01 9.4760.02
aTissues from healthy mice fed standard diet over seven days.
btissues from healthy mice fed Curcuma extract over seven days.
cpEC50 = –log EC50. EC50 values are the means6 SE of at least four independent
experiments and were calculated by a non linear regression curve-fitting
computer program (47).
dpA2 values 6 SE were calculated from Schild plots [48] constrained to slope –
1.0 [49]). pA2 is the positive value of the intercept of the line derived by plotting
log (DR –1) vs log [antagonist]. The log (DR –1) was calculated from three
different antagonist concentrations, and each concentration was tested from
four to six times. Dose-ratio (DR) values represent the ratio of the potency of the
agonist carbachol (EC50) in the presence of the antagonist and in its absence.
Parallelism of concentration–response curves was checked by linear regression,
and slopes were tested for significance (p,0.05).
doi:10.1371/journal.pone.0044650.t003
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Figure 6. Potency of CCh (pD2) and Atropine (pA2) on the ileum (a, b, c) and on the colon (d, e, f) from mice with chronic colitis. 1:
control mice, 2: chronic DSS induced colitis, 3: DSS chronic colitis mice assuming standard diet over 7 (a) 14 (b) and 21 (c) days after stopping DSS; 4:
DSS chronic colitis mice assuming curcuma extract over 7 (a), 14 (b) and 21 (c) days after stopping DSS. The dashed line shows the control values for
CCh pEC50. The dotted line shows the control values for Atropine pA2. When error bar are not shown these are covered with the point itself
Carbachol. The contraction induced by Carbachol and the antagonistic effects of Atropine were used as reference. In healthy animals Carbachol is by
3.55 times more potent on the ileum than on the colon. Atropine presents similar antagonistic activity on both tissues: these data have been used as
a comparison with the effect of Carbachol and Atropine on tissues from chronic colitis animals. After induction of chronic colitis, Charbacol pEC50
decreased by 8.71 times in the ileum and 2.34 times in the colon and Atropine pA2 was increased by 1.35 and 3.09 times in the ileum and the colon
respectively, compared with the corresponding intestinal segments of control mice. Curcuma administration improved the response to Carbachol in
the ileum by 9.12 times and by 2.45 times in the colon after 14 days administration; Atropine pA2 was decreased by 1.78 and 1.66 respectively in the
two intestinal segments.
doi:10.1371/journal.pone.0044650.g006
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located within the wall of the gut [52,53]. Although the
inflammation in IBD occurs in discrete regions of the gastrointes-
tinal tract, the ensuing functional alterations, among which altered
motility, are not limited to the inflamed segments [54,55] and a
reduced sympathetic regulation in uninflamed intestinal tracts has
been demonstrated [12]. The development of intestinal dysmotility
may in turn result in abnormal growth of intestinal microflora,
subsequently inducing a translocation of bacteria or bacterial
products through the impaired mucosal barrier [56].
In humans, it is under debate whether IBD is associated with
hyper or hypomotility [7,8,57]. Reduced haustra formation, but
increased colonic propulsive motility and diarrhea seem to be
present [58,59]. DSS colitis shares clinical and histopathological
features of UC and reproduces a model of chemically driven
colitis, where the damage of the epithelium is related to
inflammation without an immune component. In our system, this
model represents a good way to induce inflammation in the colon
and to study its effect on motility. Conflicting data exist about the
effect of DSS on intestinal motility in the experimental animal.
Spontaneous phasic contractions and Carbachol-evoked contrac-
tions of distal colon smooth muscles have been found diminished
by DSS [11,60–62]. Conversely, increased Carbachol-evoked
contractions and colonic smooth muscle hypercontractility were
reported [63]. These findings may correlate with differences in
experimental conditions, strain and gender differences in the
susceptibility of DSS-colitis. In view of the possible gene
differences, we have used male Balb/c mice: Balb/c mice are a
strain commonly used for all-purpose laboratory investigations.
Moreover males have been preferred over females due to the
phasic influences of sexual hormones on gastrointestinal motility.
In the present investigation, DSS induces deep disturbances in
basal motor activity of ileum and colon: it is worthwhile noting
that in acute colitis a hyperexcitability of the ileum is observed
associated with a depressed motor activity in the colon, while a
severe hyperexcitability is present both in ileum and in colon in the
chronic colitis model. The abolition of any motor activity of the
colon in acute experimental colitis is in agreement with the clinical
condition of the toxic megacolon. We have chosen as reference of
disturbed motility the ileal and colonic response to Carbachol and
the inhibitory effect of Atropine on the Carbachol induced
contraction. Carbachol and Atropine are respective agonist and
antagonist at cholinergic muscarinic receptors. Both agonist and
antagonist bind to the cholinergic receptors M(2) and M(3),
present in mice small intestine and colon cellular membrane. In
the present investigation, we have induced both chronic and acute
colitis in mice, since the chronic model is more suitable for
Curcuma treatment. The muscarinic receptor agonist Carbachol
generated a smaller contractile force in the DSS-treated mice than
in normal mice: this was the case both in the inflamed colonic
strips and in the normal ileal segments. The altered response to the
antagonist is a further confirmation that the cellular membrane,
where not anatomically altered, as is the case with the ileum, is
functionally altered. In this study we show that, in control
conditions, Carbachol effect is more potent in the ileum than in
the colon, while the antagonistic effect of Atropine is similar. In
vitro, Curcuma exerts an inhibition of intestinal basal and
Carbachol induced contraction both in the ileum and the colon:
this effect is non-competitive and reversible. The inhibition of
basal intestinal motility demonstrates a direct effect on the
intestinal muscular cells. The inhibition of Carbachol response is
stronger in the ileum while the antagonistic effect of Atropine is
increased in both. When orally administered to healthy animals,
Curcuma has similarly shown a direct myorelaxant activity and an
inhibition of Carbachol response on the ileum and colon, stronger
on the former than on the latter. The effect of Atropine is
conversely increased on both the intestinal tracts. To our
knowledge, this is the first report of a myorelaxant effect of
Curcuma longa both in the normal ileum and colon and in an
experimental colitis model. The present experiments, in agree-
ment with most of the authors, confirm that Carbachol-induced
contractions are reduced in the colon in the DSS-mouse colitis
model: in addition, in the present investigation, defective
Carbachol evoked contractions have been documented also in
the ileum. In acute and chronic colitis, Curcuma extract added
diet improves the ileal and colonic motility: in the chronic colitis
model, 14 days Curcuma administration restores the motility
pattern in the colon and in the ileum, but after a longer Curcuma
extract oral administration, once the mucosal repair is achieved,
the myorelaxant effect of Curcuma is prevalent in both the
intestinal segments and the inhibitory effect of Curcuma on the
colonic muscular layers is predominant, showing that the
inhibition on the muscular layers is independent of the anti-
inflammatory effect. The potency of the inhibitory effect of
Curcuma Longa on the intestinal motility is not powerful: this is
not surprising since Curcuma is a natural substance and this
should be considered in the translation from the animal model to
human pathology.
In conclusion, Curcuma extract exerts a myorelaxant effect on
the ileum and colon independent of the anti-inflammatory effect.
The mechanism of action is due both to a direct myorelaxant
effect on the intestinal muscle layers and to a non-competitive and
reversible inhibition of the cholinergic agent. It was beyond the
aim of the present paper to investigate the mechanism underlying
this effect. The present study provides the rationale for the use of
Curcuma Longa in motility disorders of IBD and suggests a
possible application to functional motor disturbances of the
gastrointestinal tract, due to the myorelaxant effect on the normal
intestine, independent of the anti-inflammatory activity.
Supporting Information
Figure S1 Effect of acute (a) and chronic (b) DSS
administration on colon length, followed by curcuma
extract (200 mg/kg) or standard diet. In the acute colitis
model mice received DSS (5%) in drinking water over 7 days
followed by seven days water; in the chronic colitis model, they
received DSS (2.5%) over 7 days followed by 14 days water per
cycle, for a total of three cycles. After colitis induction they were
fed either curcuma extract or standard diet respectively over 7 and
21 days. a1) control. a2) acute colitis.a3) acute colitis followed.by
curcuma over 7 days. a4) acute colitis followed by standard diet
over 7 days. b1) control. b2) chronic colitis. b3) chronic colitis
followed by curcuma extract over 21 days. b4) chronic colitis
followed by standard diet over 21 days. Each point is the mean 6
SD (6 determinations). Significance: (a) 1vs 2: p,0.005; 1vs 3:
p,0.005; 1vs 4: p,0.001; 2 vs 3: p,0.05; 2 vs 4: p,0.05; 3vs 4: p
ns. (b) 1vs 2: p,0.0001; 1vs 3: p,0.005; 1vs 4: p,0.0005; 2 vs 3:
p,0.01; 2 vs 4: p,0.05; 3 vs 4: p ns.
(TIF)
Figure S2 The Disease Activity Index in the acute (a)
and chronic colitis (b) model. The DAIs were calculated as
described in the Materials and Method section. Each point is the
mean 6 SD (6 determinations). Where error bars are not shown,
these are covered by the point itself. Significance: (a) From day 4
on: DSS vs control tap water: p,0.0001. (b) From day 6 on: DSS
vs control tap water: p,0.0001.
(TIF)
Intestinal Myorelaxant Effect of Curcuma
PLOS ONE | www.plosone.org 10 September 2012 | Volume 7 | Issue 9 | e44650
Figure S3 The DAI in mice fed curcuma (red) or
standard diet (black) after acute (a) and chronic (b)
colitis induction. The DAIs were calculated as described in the
Materials and Method section. Each point is the mean 6 SD (6
determinations). Significance: (a) 7 days after stopping DSS,
Curcuma extract vs control diet, p,0.0001. (b) 14 days after
stopping DSS, Curcuma extract vs standard diet: p,0.05; 21 days:
p,0.005.
(TIF)
Table S1 Parameters investigated for the evaluation of
the Disease Activity Index.
(DOC)
Table S2 Antagonist affinities, expressed as IC50 Val-
ues, in the different mouse gut smooth muscle seg-
ments.
(DOC)
Table S3 Potency of Chrabacol and Atropine on isolated
mice tissues.
(DOC)
Table S4 Agonist (Carbachol) and antagonist (Atropine)
affinities expressed as pEC50 or pA2 respectively in the
isolated mice ileum and distal colon.
(DOC)
Table S5 Agonist (Carbachol) and antagonist (Atropine)
affinities expressed as pEC50 or pA2 respectively in the
isolated mice ileum and distal colon.
(DOC)
Text S1 Supporting information.
(DOCX)
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